المؤلفون: Marguerite Kandel, Aurélie Bardet, Stéphane Dalle, Clara Allayous, Laurent Mortier, Bernard Guillot, Caroline Dutriaux, Marie-Thérèse Leccia, Sophie Dalac, Henri Montaudie, Philippe Saiag, Delphine Legoupil, Florence Brunet-Possenti, Jean-Philippe Arnault, Julie De Quatrebarbes, Marie Beylot-Barry, Eve Maubec, Thierry Lesimple, François Aubin, Jean-Jacques Grob, Florence Granel-Brocard, Pierre-Emmanuel Stoebner, Alain Dupuy, Brigitte Dreno, Stefan Michiels, Céleste Lebbe, Isabelle Borget

المصدر: Current Oncology, Vol 29, Iss 12, Pp 9255-9270 (2022)

مصطلحات موضوعية: cost-effectiveness analysis, advanced melanoma, real-life clinical practice, immunotherapy, targeted therapy, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/1718-7729/29/12/725Test; https://doaj.org/toc/1198-0052Test; https://doaj.org/toc/1718-7729Test

الوصول الحر: https://doaj.org/article/029219c40f474f67aac932d94f25d323Test

المؤلفون: Candice Hober, Lisa Fredeau, Anne Pham-Ledard, Marouane Boubaya, Florian Herms, Philippe Celerier, François Aubin, Nathalie Beneton, Monica Dinulescu, Arnaud Jannic, Nicolas Meyer, Anne-Bénédicte Duval-Modeste, Laure Cesaire, Ève-Marie Neidhardt, Élodie Archier, Brigitte Dréno, Candice Lesage, Clémence Berthin, Nora Kramkimel, Florent Grange, Julie de Quatrebarbes, Pierre-Emmanuel Stoebner, Nicolas Poulalhon, Jean-Philippe Arnault, Safia Abed, Bertille Bonniaud, Sophie Darras, Valentine Heidelberger, Suzanne Devaux, Marie Moncourier, Laurent Misery, Sandrine Mansard, Maxime Etienne, Florence Brunet-Possenti, Caroline Jacobzone, Romain Lesbazeilles, François Skowron, Julia Sanchez, Stéphanie Catala, Mahtab Samimi, Youssef Tazi, Dominique Spaeth, Caroline Gaudy-Marqueste, Olivier Collard, Raoul Triller, Marc Pracht, Marc Dumas, Lucie Peuvrel, Pierre Combe, Olivier Lauche, Pierre Guillet, Yves Reguerre, Ingrid Kupfer-Bessaguet, David Solub, Amélie Schoeffler, Christophe Bedane, Gaëlle Quéreux, Sophie Dalac, Laurent Mortier, Ève Maubec

المصدر: Cancers, Vol 13, Iss 14, p 3547 (2021)

مصطلحات موضوعية: PD-1–blocking antibody, cemiplimab, cutaneous squamous cell carcinoma, real-life setting, immunocompromised, chronic dermatosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/13/14/3547Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/d9295d94cea242f3a1e1c42dd047374aTest

المؤلفون: Ondine Becquart, Bastien Oriano, Stéphane Dalle, Laurent Mortier, Marie Thérèse Leccia, Caroline Dutriaux, Sophie Dalac, Henri Montaudié, Julie De Quatrebarbes, Florence Brunet-Possenti, Philippe Saiag, Thierry Lesimple, Marie Beylot-Barry, Francois Aubin, Pierre-Emmanuel Stoebner, Jean-Philippe Arnault, Brigitte Dreno, Raphael Porcher, Celeste Lebbe, Bernard Guillot

المصدر: Cancers, Vol 13, Iss 12, p 3042 (2021)

مصطلحات موضوعية: melanoma, targeted therapy, elderly people, side effects, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2072-6694/13/12/3042Test; https://doaj.org/toc/2072-6694Test

الوصول الحر: https://doaj.org/article/52e1bc0b33964b3eb467b92106cad926Test

المؤلفون: Laure Cayrefourcq, Aurélie De Roeck, Caroline Garcia, Pierre-Emmanuel Stoebner, Fanny Fichel, Françoise Garima, Françoise Perriard, Jean-Pierre Daures, Laurent Meunier, Catherine Alix-Panabières

المصدر: Cells, Vol 8, Iss 7, p 755 (2019)

مصطلحات موضوعية: circulating tumor cells, melanoma, liquid biopsy, EPISPOT, CellSearch®, Cytology, QH573-671

وصف الملف: electronic resource

العلاقة: https://www.mdpi.com/2073-4409/8/7/755Test; https://doaj.org/toc/2073-4409Test

الوصول الحر: https://doaj.org/article/2e7ae4ceac3d4eb99b78ca0a488ccc9eTest

المؤلفون: François Habib, Arnaud Ly, Pierre-Emmanuel Stoebner

المصدر: Annales de Dermatologie et de Vénéréologie - FMC. 3:167-180

مصطلحات موضوعية: Ocean Engineering, Safety, Risk, Reliability and Quality

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::610ccc6ebfcdae3a56a1ce191faf5a6bTest
https://doi.org/10.1016/j.fander.2023.01.002Test

المؤلفون: Manon Girod, Stéphane Dalle, Laurent Mortier, Sophie Dalac, Marie-Thèrèse Leccia, Caroline Dutriaux, Henri Montaudié, Julie de Quatrebarbes, Thierry Lesimple, Florence Brunet-Possenti, Philippe Saiag, Eve Maubec, Delphine Legoupil, Pierre-Emmanuel Stoebner, Jean Philippe Arnault, Wendy Lefevre, Celeste Lebbe, Olivier Dereure

المصدر: JCO precision oncology. 6

مصطلحات موضوعية: Proto-Oncogene Proteins B-raf, Mitogen-Activated Protein Kinase Kinases, Cancer Research, Oncology, Mutation, Humans, Neoplasms, Second Primary, Prospective Studies, Melanoma, Protein Kinase Inhibitors

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::296c259a9e95eff6c39b540f79e35811Test
https://pubmed.ncbi.nlm.nih.gov/36356284Test

المؤلفون: Quentin Samaran, Pierre-Emmanuel Stoebner, Bernadette Ovtchinnikoff

المصدر: Dermatologic Surgery. 49:625-626

مصطلحات موضوعية: Surgery, Dermatology, General Medicine

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::cb7bf24a8409e396fe6221efda914ca7Test
https://doi.org/10.1097/dss.0000000000003796Test

المؤلفون: Anne Bonhoure, Laurent Henry, Claudia Bich, Lionel Blanc, Blanche Bergeret, Marie‐Pierre Bousquet, Olivier Coux, Pierre‐Emmanuel Stoebner, Michel Vidal

المصدر: Traffic (Copenhagen, Denmark)REFERENCES. 23(5)

مصطلحات موضوعية: Agglutination, Cytoplasm, Proteasome Endopeptidase Complex, Structural Biology, Galectin 3, Proteolysis, Genetics, Humans, Cell Biology, Molecular Biology, Biochemistry

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1d0714fd7227df4655ae9e8737c21edTest
https://pubmed.ncbi.nlm.nih.gov/35466519Test

المؤلفون: Léo Plaçais, Stéphane Dalle, Olivier Dereure, Sabiha Trabelsi, Sophie Dalac, Delphine Legoupil, Henri Montaudié, Jean-Philippe Arnault, Julie De Quatrebarbes, Philippe Saiag, Florence Brunet-Possenti, Thierry Lesimple, Eve Maubec, François Aubin, Florence Granel-Brocard, Jean-Jacques Grob, Pierre-Emmanuel Stoebner, Clara Allayous, Bastien Oriano, Caroline Dutriaux, Laurent Mortier, Céleste Lebbe

المساهمون: AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Immunologie des maladies virales, auto-immunes, hématologiques et bactériennes (IMVA-HB), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre Léon Bérard [Lyon], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Pathogenesis and Control of Chronic and Emerging Infections (PCCEI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université des Antilles (UA)-Etablissement français du don du sang [Montpellier]-Université de Montpellier (UM), Centre Hospitalier Universitaire [Grenoble] (CHU), Service de Dermatologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Laboratoire de Neurosciences de Brest (LNB), Université de Brest (UBO), Service de Dermatologie [Nice], Hôpital Archet 2 [Nice] (CHU), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), CHU Amiens-Picardie, Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Hôpital Ambroise Paré [AP-HP], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CRLCC Eugène Marquis (CRLCC), Hôpital Avicenne [AP-HP], Université Paris 13 (UP13), Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Hôpital Universitaire Carémeau [Nîmes] (CHU Nîmes), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Service de Dermatologie [AP-HP Hôpital Saint-Louis], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Hôpital Hôtel-Dieu [Paris], CHU Bordeaux [Bordeaux], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)

المصدر: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 2022, 81 (10), pp.1445-1452. ⟨10.1136/ard-2022-222186⟩

مصطلحات موضوعية: MESH: Humans, MESH: Immune Checkpoint Inhibitors, MESH: Melanoma, Immunology, Autoimmunity, MESH: Retrospective Studies, Therapeutics, MESH: Antineoplastic Agents, Immunological, MESH: Case-Control Studies, General Biochemistry, Genetics and Molecular Biology, MESH: Prospective Studies, Autoimmune Diseases, Antineoplastic Agents, Immunological, Rheumatology, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Immune System Diseases, MESH: Autoimmune Diseases, MESH: Immune System Diseases, Case-Control Studies, Immunology and Allergy, Humans, Prospective Studies, Immune Checkpoint Inhibitors, Melanoma, Retrospective Studies

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6939047d134b5d37055588258f142673Test
https://pubmed.ncbi.nlm.nih.gov/35788496Test

المؤلفون: Florence Granel-Brocard, Alain Dupuy, D. Legoupil, Jean-Jacques Grob, Marie Beylot-Barry, Marie-Thérèse Leccia, Jean-Philippe Arnault, Florence Brunet-Possenti, A. Bardet, Pierre-Emmanuel Stoebner, Céleste Lebbe, Stéphane Dalle, Eve Maubec, Clara Allayous, Isabelle Borget, Bernard Guillot, Brigitte Dréno, Julie DeQuatrebarbes, Philippe Saiag, Laurent Mortier, Marguerite Kandel, Sophie Dalac, Caroline Dutriaux, Thierry Lesimple, Stefan Michiels, Henri Montaudié, François Aubin

المساهمون: Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Institut Gustave Roussy (IGR), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de biostatistique et d'épidémiologie (SBE), Direction de la recherche clinique [Gustave Roussy], Institut Gustave Roussy (IGR)-Institut Gustave Roussy (IGR), Immunologie humaine, physiopathologie & immunothérapie (HIPI (UMR_S_976 / U976)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Thérapies Laser Assistées par l'Image pour l'Oncologie - U 1189 (ONCO-THAI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Groupe hospitalier Saint-André, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Universitaire [Grenoble] (CHU), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Hôpital Ambroise Paré [AP-HP], Centre Hospitalier Universitaire de Nice (CHU Nice), Service de dermatologie [CHU d'Amiens-Picardie], CHU Amiens-Picardie, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de dermatologie, vénéreologie et cancérologie cutanée [Hôpital de la Timone - APHM], Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Annecy-Genevois [Saint-Julien-en-Genevois], Service de dermatologie [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux], CRLCC Eugène Marquis (CRLCC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Avicennes University Hospital, Service de Dermatologie et Allergologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), Service de Dermatologie [Rennes] = Dermatology [Rennes], CHU Pontchaillou [Rennes], Service de dermatologie [Nantes], Université de Nantes (UN)-Centre hospitalier universitaire de Nantes (CHU Nantes), Oncostat (U1018 (Équipe 2)), Institut Gustave Roussy (IGR)-Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Saclay, Centre Léon Bérard [Lyon], AP-HP. Université Paris Saclay, Amgen Pfizer Merck Novartis Roche Janssen Biotech Meso Scale Diagnostics, MSD Array BioPharma Takeda Pharmaceutical Company Sanofi Pasteur British Microcirculation Society, BMS Institut National Du Cancer, INCa: DOC 16‐009, This work was supported by the French National Cancer Institute (DOC 16‐009)., Stéphane Dalle reports institutional research funding Roche, institutional research funding and nonfinancial support from Bristol‐Myers Squibb (BMS), and an immediate family member who is employed by Sanofi and owns stock or other ownership interest in the company. Aurélie Bardet was employed by Roche and held stock and other ownership interest in the company until March of 2018. Clara Allayous reports nonfinancial support from BMS, Amgen, and Roche outside the submitted work. Laurent Mortier reports personal fees and nonfinancial support from Roche, Novartis, BMS, and Merck Sharp & Dohme (MSD) outside the submitted work. Caroline Dutriaux reports personal fees from Roche, BMS, Novartis, MSD, and Pierre Fabre Laboratories outside the submitted work. Philippe Saiag reports research funding and personal fees from Roche, grants, personal fees, and nonfinancial support from BMS, MSD, Novartis, and Pierre Fabre Laboratories, and personal fees from Array, Sanofi, and Merck, all outside the submitted work. Henri Montaudié reports institutional research funding from LeoPharma, institutional research funding, personal fees, and nonfinancial support from BMS, personal fees from Pierre Fabre Laboratories and MSD, and nonfinancial support from Novartis, all outside the submitted work. Jean‐Phillipe Arnault reports institutional research funding and personal fees from BMS and institutional research funding from Novartis outside the submitted work. Jean‐Jacques Grob reports personal fees and nonfinancial support from BMS, Roche, MSD, Novartis, Merck, Amgen, Pierre Fabre Laboratories, Sanofi, and Pfizer and nonfinancial support from Amgen, all outside the submitted work. Julie De Quatrebarbes reports nonfinancial support from BMS, MSD, and Janssen outside the submitted work. Thierry Lesimple reports research funding and personal fees from Roche and personal fees from BMS, MSD, Novartis, Pierre Fabre Laboratories, and Incyte, all outside the submitted work. François Aubin reports personal fees and nonfinancial support from Novartis, MSD, and Roche outside the submitted work. Eve Maubec reports grants, personal fees, and nonfinancial support from MSD, personal fees from Sanofi and Novartis, personal fees and nonfinancial support from BMS, and nonfinancial support from Pierre Fabre Laboratories, all outside the submitted work. Stefan Michiels reports personal fees from IDDI Belgium, Janssen Cilag France, Hexal, Johnson & Johnson, Ipsen, Genticel, Mabxience, Steba, IQVIA, Roche, Sensorion, Biophytis, and Servier, all outside the submitted work. Céleste Lebbe reports institutional research funding, personal fees, and nonfinancial support from BMS, institutional funding and personal fees from Roche, personal fees and nonfinancial support from MSD, and personal fees from Aventis, Novartis, Amgen, Pierre Fabre Laboratories, Pfizer, and Incyte, all outside the submitted work. Isabelle Borget reports research funding from the BMS Foundation during the course of the study and personal fees from Roche, Janssen, CSC Behring, Novartis, and Takeda outside the submitted work. The remaining authors made no disclosures., Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Paris (UP), Hôpital de la Timone [CHU - APHM] (TIMONE)-Assistance Publique - Hôpitaux de Marseille (APHM)-Aix Marseille Université (AMU)

المصدر: Cancer
Cancer, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩
Cancer, Wiley, 2020, 126 (3), pp.611-618. ⟨10.1002/cncr.32554⟩

مصطلحات موضوعية: Male, Cancer Research, MESH: Adolescent, Adult, Aged, 80 and over, Cohort Studies, Disease Progression, Female, France / epidemiology, Humans, Disease, Clinical practice, Targeted therapy, 0302 clinical medicine, Second line, Quality of life, Advanced disease, Medicine, Molecular Targeted Therapy, Prospective Studies, 030212 general & internal medicine, Neoplasm Metastasis, Melanoma, MESH: Immunotherapy, Melanoma / epidemiology, Melanoma / immunology, Melanoma / pathology, Melanoma / therapy, MESH: Middle Aged, Neoplasms, Second Primary / epidemiology, Young Adult, Real-life, Neoplasms, Second Primary, Middle Aged, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Cohort, France, Immunotherapy, medicine.medical_specialty, Adolescent, Metastatic melanoma, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Internal medicine, In real life, Survival rate, Aged, business.industry, MESH: Neoplasms, Second Primary / immunology, Neoplasms, Second Primary / pathology, Quality of Life, business, [SDV.MHEP.DERM]Life Sciences [q-bio]/Human health and pathology/Dermatology

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e7cc27d9b011eb68b46c2a487331edaTest
https://doi.org/10.1002/cncr.32554Test